Foghorn BAF Complex Modulators Patent Application

The EPO published international patent application EP4096667A1 for Foghorn Therapeutics Inc. covering modulators of the BAF (BRG1-associated factor) chromatin remodeling complex. The application claims priority from earlier filings and covers heterocyclic compounds classified across multiple C07D subgroups including C07D235/14, C07D405/12, C07D405/14, C07D417/10, C07D417/14, C07D471/04, C07D487/10, C07D513/04, and C07D519/00, as well as pharmaceutical preparations classified under A61K31/495 and A61K45/06 with a stated therapeutic use in cancer treatment (A61P35/00).

For pharmaceutical developers and biotech companies working in the chromatin remodeling space, this patent publication establishes a priority date for Foghorn's BAF modulator technology across all 44 EPO-designated contracting states. Parties developing competitive compounds in this therapeutic area should conduct freedom-to-operate analyses to assess potential overlap with the claimed compounds and methods. The patent's broad C07D coverage suggests a scaffold-hopping strategy that may extend to multiple compound families.